These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11071627)

  • 1. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia.
    Reich S; Bührer C; Henze G; Ohlendorf D; Mesche M; Sinha P; Kage A; Müller C; Vetter B; Kulozik AE
    Blood; 2000 Nov; 96(10):3357-63. PubMed ID: 11071627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
    Collins AF; Pearson HA; Giardina P; McDonagh KT; Brusilow SW; Dover GJ
    Blood; 1995 Jan; 85(1):43-9. PubMed ID: 7528572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
    Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study.
    Domenica Cappellini M; Graziadei G; Ciceri L; Comino A; Bianchi P; Porcella A; Fiorelli G
    Blood Cells Mol Dis; 2000 Feb; 26(1):105-11. PubMed ID: 10772882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia.
    Nisli G; Kavakli K; Aydinok Y; Oztop S; Cetingül N; Basak N
    Acta Haematol; 1997; 98(4):199-203. PubMed ID: 9401497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butyrate trials.
    Cappellini MD; Graziadei G; Ciceri L; Comino A; Bianchi P; Pomati M; Fiorelli G
    Ann N Y Acad Sci; 1998 Jun; 850():110-9. PubMed ID: 9668533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal globin stimulation during a short-term trial of erythropoietin in HbS/beta-thalassemia patients.
    Bourantas KL; Georgiou I; Seferiadis K
    Acta Haematol; 1994; 92(2):79-82. PubMed ID: 7529455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy.
    Breymann C; Fibach E; Visca E; Huettner C; Huch A; Huch R
    J Matern Fetal Med; 1999; 8(1):1-7. PubMed ID: 10052837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
    Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
    Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why are hemoglobin F levels increased in HbE/beta thalassemia?
    Rees DC; Porter JB; Clegg JB; Weatherall DJ
    Blood; 1999 Nov; 94(9):3199-204. PubMed ID: 10556208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia.
    Thein SL
    Blood Rev; 2012 Apr; 26 Suppl 1():S35-9. PubMed ID: 22631042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes.
    Brancaleoni V; Moukhadder HM; Consonni D; Koussa S; Di Pierro E; Cappellini MD; Taher A
    Ann Hematol; 2019 Apr; 98(4):833-840. PubMed ID: 30506348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
    Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
    Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
    Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
    Cappellini MD; Porter J; Origa R; Forni GL; Voskaridou E; Galactéros F; Taher AT; Arlet JB; Ribeil JA; Garbowski M; Graziadei G; Brouzes C; Semeraro M; Laadem A; Miteva D; Zou J; Sung V; Zinger T; Attie KM; Hermine O
    Haematologica; 2019 Mar; 104(3):477-484. PubMed ID: 30337358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical observation on YiSuiShengXueGranule on treating 156 patients with beta-thalassemia major and the molecular mechanism study.
    Fang S; Wu Z; Zhang X; Liu Y; Wang W; Chai L; Cai H; Yi J; Wang L; Chen Y; Lv X; Huang Y; Wang R; Chen P
    Biol Pharm Bull; 2007 Nov; 30(11):2084-7. PubMed ID: 17978480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.